These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

287 related items for PubMed ID: 37140706

  • 1. Real-World Modifications of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Hyperkalemia Initiating Sodium Zirconium Cyclosilicate Therapy: The OPTIMIZE I Study.
    Agiro A, An A, Cook EE, Mu F, Chen J, Desai P, Oluwatosin Y, Pollack CV.
    Adv Ther; 2023 Jun; 40(6):2886-2901. PubMed ID: 37140706
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia.
    Kanda E, Rastogi A, Murohara T, Lesén E, Agiro A, Arnold M, Chen G, Yajima T, Järbrink K, Pollack CV.
    BMC Nephrol; 2023 Jan 19; 24(1):18. PubMed ID: 36658531
    [Abstract] [Full Text] [Related]

  • 4. [Effect of hyperkalemia and RAASi nonadherence on patients affected by heart failure or chronic kidney disease].
    Degli Esposti L, Perrone V, Giacomini E, Sangiorgi D, Alessandrini D, Santoro A.
    G Ital Nefrol; 2019 Sep 24; 36(5):. PubMed ID: 31580544
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Sodium zirconium cyclosilicate reconciles management of hyperkalemia and continuity of renin-angiotensin-aldosterone system inhibitors: a retrospective observational study.
    Kimura W, Minatoguchi S, Mizuno T, Koide S, Hayashi H, Hasegawa M, Inaguma D, Tsuboi N.
    J Nephrol; 2024 Jan 24; 37(1):171-179. PubMed ID: 37608241
    [Abstract] [Full Text] [Related]

  • 7. Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom.
    Linde C, Bakhai A, Furuland H, Evans M, McEwan P, Ayoubkhani D, Qin L.
    J Am Heart Assoc; 2019 Nov 19; 8(22):e012655. PubMed ID: 31711387
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The LIFT trial: study protocol for a double-blind, randomised, placebo-controlled trial of K+-binder Lokelma for maximisation of RAAS inhibition in CKD patients with heart failure.
    Murphy D, Ster IC, Kaski JC, Anderson L, Banerjee D.
    BMC Nephrol; 2021 Jul 06; 22(1):254. PubMed ID: 34229607
    [Abstract] [Full Text] [Related]

  • 10. Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study.
    Jun M, Jardine MJ, Perkovic V, Pilard Q, Billot L, Rodgers A, Rogers K, Gallagher M.
    PLoS One; 2019 Jul 06; 14(3):e0213192. PubMed ID: 30845156
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness analysis of sodium zirconium cyclosilicate for hyperkalemia among patients with chronic kidney disease or heart failure in Kuwait.
    Elsisi GH, Mahmoud MMI, Al-Humood K, Al-Yousef A.
    J Med Econ; 2024 Jul 06; 27(1):253-265. PubMed ID: 38318718
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors Secondary to Hyperkalemia Translates into Higher Cardiorenal Outcomes.
    An J, Zhou H, Ni L, Harrision TN, Wei R, Agiro A, Brahmbhatt YG, Oluwatosin Y, Schilling CG, Sim JJ.
    Am J Nephrol; 2023 Jul 06; 54(7-8):258-267. PubMed ID: 37231821
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of sodium zirconium cyclosilicate for advanced chronic kidney patients in Singapore.
    Chay J, Choo JCJ, Finkelstein EA.
    Nephrology (Carlton); 2024 May 06; 29(5):278-287. PubMed ID: 38443742
    [Abstract] [Full Text] [Related]

  • 16. A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure.
    Ward T, Lewis RD, Brown T, Baxter G, de Arellano AR.
    BMC Nephrol; 2023 Mar 09; 24(1):47. PubMed ID: 36890464
    [Abstract] [Full Text] [Related]

  • 17. Hyperkalemia treatment modalities: A descriptive observational study focused on medication and healthcare resource utilization.
    Desai NR, Rowan CG, Alvarez PJ, Fogli J, Toto RD.
    PLoS One; 2020 Mar 09; 15(1):e0226844. PubMed ID: 31910208
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Maintaining Renin-Angiotensin-Aldosterone System Inhibitor Treatment with Patiromer in Hyperkalaemic Chronic Kidney Disease Patients: Comparison of a Propensity-Matched Real-World Population with AMETHYST-DN.
    Chinnadurai R, Rengarajan S, Budden JJ, Quinn CM, Kalra PA.
    Am J Nephrol; 2023 Mar 09; 54(9-10):408-415. PubMed ID: 37725919
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.